An IL-1.beta. binding molecule, in particular an antibody to human IL-1.beta., especially a human antibody to human IL-1.beta. is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.